US Proteomics Market Report: Trends, Growth and Forecast (2026-2032)

US Proteomics Market Segmentation Analysis

By Technology

• Spectroscopy
  • Mass Spectroscopy
  • NMR Spectroscopy
  • CD Spectroscopy
• Chromatography
  • HPLC Chromatography
  • Affinity Chromatography
  • Supercritical Fluid Chromatography
  • Ion Exchange Chromatography
• Electrophoresis
  • Gel Electrophoresis
  • Capillary Electrophoresis
• Protein Microarray
  • Biochip
  • Lab-on-Chip
  • Protein Chip
  • Microarray Instrument
  • Integrated System
  • Microarray Scanner
  • Arrayers
• Crystallography
  • Surface Plasma Resonance
  • Fractionation
  • Others

The segment with highest market share under the Technology is Mass Spectrometry, accounting for approximately 45% of the total market. This commanding position reflects the deep structural alignment between mass spectrometry analytical capabilities and the specific protein identification, biomarker discovery, and molecular characterization requirements of the American research and pharmaceutical development community, where detection sensitivity, molecular specificity, and comprehensive analytical coverage make mass spectrometry-based platforms the reference technology standard across oncology research, translational medicine, and therapeutic development workflows. With nearly half of total market value concentrated within a single technology category, Mass Spectrometry defines the research methodology priorities, analytical platform investment frameworks, and competitive positioning strategies of the US proteomics market.

The structural leadership of Mass Spectrometry is sustained by the analytical performance and methodological maturity that have established this technology as the gold standard for protein-centric discovery research across academic and pharmaceutical environments throughout the United States. As multi-omics integration advances and precision medicine research demands increasingly sophisticated protein profiling across complex biological systems, mass spectrometry platforms are progressively evolving to support higher-throughput capacity, improved quantification accuracy, and more seamless integration with genomic, imaging, and clinical data streams. This technological evolution positions established mass spectrometry platform providers to capture both sustained replacement demand and expanding application breadth procurement across the American research and pharmaceutical development market base. The segment's structural dominance as the market's primary technology revenue contributor is expected to consolidateover the forecast period.

By Application

• Drug Discovery
  • Target Discovery
  • Lead Identification
  • Lead Optimization
  • Preclinical Studies
• Clinical Diagnostics
  • Oncology
  • Infectious Diseases
  • Diabetes
  • Neurological Disorder
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Others

The segment with highest market share under the Application is Drug Discovery, accounting for approximately 40% of the total market. This dominant position reflects the foundational role of protein-level analysis in pharmaceutical research where biomarker identification, therapeutic target validation, and mechanism-of-action characterization directly support drug candidate selection, clinical development pathway optimization, and translational research acceleration across the market's most commercially significant pharmaceutical development programs. With two-fifths of total market value anchored in drug discovery applications, this segment defines the research investment priorities, analytical capability requirements, and competitive positioning strategies that shape proteomics platform development and supplier competitive advantage across the American market.

The structural leadership of Drug Discovery is being actively sustained by the accelerating pharmaceutical innovation momentum and the progressively more protein-centric approach to early-stage drug development that characterizes contemporary therapeutic research programs across the United States. The FDA's documentation of 46 novel drug approvals in 2025 confirms that pharmaceutical development activity is sustaining robust expansion momentum whose success increasingly depends on protein-level biological insights that advanced proteomics platforms uniquely deliver at discovery and preclinical development stages. The National Cancer Institute's quantification of pan-cancer proteogenomics data across 1,043 patients spanning 10 cancer types, coupled with the identification that fewer than 200 proteins are targeted by FDA-approved cancer drugs, establishes that substantial therapeutic target discovery opportunity remains available for proteomics-enabled drug development programs. As pharmaceutical research becomes more targeted and evidence-driven, the commercial importance of proteomics tools in supporting earlier, more confident candidate selection decisions and reducing late-stage development failures is driving sustained and expanding investment in proteomics platform procurement across the American pharmaceutical development ecosystem. The Drug Discovery segment's position as the market's dominant application anchor and primary revenue driver is expected to strengthenover the forecast period.

List of Companies Covered in US Proteomics Market

The companies listed below are highly influential in the US proteomics market, with a significant market share and a strong impact on industry developments.

• Bio-Techne
• Standard BioTools
• Illumina
• Thermo Fisher Scientific
• Danaher (SCIEX)
• Agilent Technologies
• Bruker
• Waters Corporation
• Revvity
• Shimadzu Scientific Instruments

Market News & Updates

• OmniActive Health Technologies, 2025:

  OmniActive announced that the U.S. FDA acknowledged Lutemax Free Lutein for use in infant formula, and the company said this regulatory milestone opens a new category for its flagship lutein ingredient by giving infant-formula manufacturers a differentiated carotenoid source to support infant eye and brain development. For the U.S. phytonutrients market, this is a highly significant update because it expands lutein’s addressable market into one of the most tightly regulated nutrition segments and strengthens the commercial relevance of carotenoid-based phytonutrients in early-life nutrition

• Lycored, 2025:

  Lycored announced at IFT FIRST in Chicago the debut of three superstable, nature-based color emulsions—including new yellow and orange shades positioned as replacements for Yellow 5 and 6—while also emphasizing that its lycopene-based red solutions can replace Red 3 and Red 40 across beverages, gummies, sauces, supplements, and fruit preparations. For the U.S. phytonutrients market, this is one of the clearest product-led developments because it directly connects carotenoid-based natural color systems with reformulation demand in the U.S. food and supplement industry, where brands are increasingly looking for stable plant-derived alternatives to synthetic dyes.